CPT code 93025 identifies a focused electrocardiographic service in which a clinician analyzes subtle T‑wave alterations to evaluate risk of ventricular arrhythmia. This targeted interpretation supports clinical decision‑making for patients at potential risk of life‑threatening ventricular tachyarrhythmias and can influence further diagnostic testing, monitoring, or therapy selection.

Key national payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides an overview of clinical context, coding description, and payer coverage considerations relevant to national stakeholders.

Readers will find a concise explanation of the clinical purpose of CPT code 93025, typical settings where the service is delivered, and the role this code plays in arrhythmia risk stratification. The report highlights common billing modifiers and lists areas where input data was not provided. It is intended to inform revenue cycle staff, clinical coders, and policy analysts about the code’s clinical meaning, expected service line, and payer landscape rather than provide state‑level rules or specific reimbursement figures.